The Curative Effect of Yikang Pill on Graves Disease and Its Influences on Autoantibodies and Adipocytokines

QIU Ze-an; DING Yuan-ting; WU Xiao-li

doi:10.11653/syfj2013220299

您当前的位置：

首页 >

文章列表页 >

The Curative Effect of Yikang Pill on Graves Disease and Its Influences on Autoantibodies and Adipocytokines

更新时间：2024-01-04

- The Curative Effect of Yikang Pill on Graves Disease and Its Influences on Autoantibodies and Adipocytokines
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 19, Issue 22, Pages: 299-302(2013)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.11653/syfj2013220299
  CLC：
- Published：2013
- 稿件说明：
移动端阅览
QIU Ze-an, DING Yuan-ting, WU Xiao-li. The Curative Effect of Yikang Pill on Graves Disease and Its Influences on Autoantibodies and Adipocytokines[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(22): 299-302.
DOI：

QIU Ze-an, DING Yuan-ting, WU Xiao-li. The Curative Effect of Yikang Pill on Graves Disease and Its Influences on Autoantibodies and Adipocytokines[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(22): 299-302. DOI： 10.11653/syfj2013220299.

摘要

目的: 探讨抑亢丸治疗毒性弥漫性甲状腺肿(Graves病

GD)的疗效及对自身抗体和脂肪细胞因子的影响。方法: 92例GD患者随机按数字法分为观察组和对照组各46例。对照组采用甲巯咪唑10 mg/次

3次/d

并根据甲状腺功能指标调整剂量。观察组在对照组治疗的基础上加用抑亢丸

7.5 g/次

2次/d。疗程为12周。记录治疗前、治疗后4、8、12周主要症状、体征积分变化;检测治疗前后血清促甲状腺素(TSH)、三碘甲状腺原氨酸(T3)、血清甲状腺素(T4)、血清游离三碘甲状腺原氨酸(FT3)、血清游离甲状腺素(FT4);检测治疗前后抗甲状腺球蛋白抗体(TGAb)、抗甲状腺微粒体抗体(TMAb)、检测过氧化物酶抗体(TPOAb)水平;检测治疗前后血清游离脂肪酸(FFA)、脂联素(APN)瘦素(LP)及抵抗素(ADSF)水平。结果: 观察组总有效率95.6%

优于对照组的82.6%(P<0.05);观察组主要症状、体征积分在8周和12周下降幅度优于对照组(P<0.01);治疗后观察组TSH水平高于对照组

FT3

FT4水平低于对照组(P<0.05或P<0.01);治疗后观察组TGAb、TMAb及TPOAb低于对照组(P<0.01);治疗后观察组FFA

APN和ADSF水平低于对照组(P<0.01)

LP水平高于对照组(P<0.01)。结论: 抑亢丸能明显改善GD临床症状

提高临床疗效

其机理可能与降低GD患者自身抗体水平

调节异常免疫有关;抑亢丸还能调节GD患者脂肪细胞因子水平

从而改善GD患者改善异常的糖脂代谢。

Abstract

Objective: The purpose is to study the curative effect of Yi Kang pill on Graves Disease (GD) and its influences on autoantibodies and adipocytokines. Method: Ninety-two cases of GD patients were randomly divided into control group (46 cases) and observation group (46 cases) according to digital method. Patients in the control group took methimazole

10 mg/time

3 times/day

adjusting the dosage according to the index of thyroid function. On the basis of treatment in the control group

patients in the observation group took Yikang pill

7.5 g/time

2 times/day. Treatment course was 12 weeks. The cardinal symptom and signs of integral change of before and after the treatment of 4

8 and 12 weeks were recorded. Serum thyroid stimulating hormone (TSH)

triiodothyronine (T3)

serum thyroxine (T4)

serum free triiodothyronine (FT3) and serum free thyroxine (FT4) were detected before and after the treatment. Levels of anti-thyroglobulin antibody (TGAb)

thyroid microsomal antibody (TMAb) and thyroperoxidase antibodies (TPOAb) were detected before and after the treatment. Levels of serum free fatty acid (FFA)

adiponectin (APN)

leptin (LP) and resistin (ADSF) were detected before and after the treatment. Result: The total effect of the observation group was 95.6%

superior to 82.6% of the control group (P<0.05). The decline range of cardinal symptom and signs of integral change of observation group was of better than that of control group in eighth weeks and twelfth weeks after the treatment (P<0.01). After treatment

TSH level of observation group was higher than the control group

while levels of T3

FT3 and FT4 were lower than the control group (P<0.05 or P<0.01). TGAb

TPOAb and TMAb of observation group were lower than the control group (P<0.01). Levels of FFA

APN and ASDF were lower than the control group (P<0.01)

while the LP level higher than the control group (P<0.01). Conclusion: Yikang Pill can obviously improve clinical symptoms of GD patient

improving the clinical curative effect. Its mechanism may be related to decrease autoantibodies levels of GD patients and to adjust abnormal immune. Yikang Pill can also regulate adipocytokines level of GD patients

further improving abnormal glucolipid metabolism of GD patients.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Compatibility of Anemarrhenae Rhizoma-Phellodendri Chinensis Cortex Couplet Medicines on Glucolipid Metabolism in Type 2 Diabetic Rats Before and After Salt-processing

Clinical Efficacy of Modified Huanglian Wendantang in Treatment of Newly Diagnosed Type 2 Diabetes Mellitus with Phlegm (Dampness)-Heat Syndrome

Related Author

Shun-ming FAN

Chun-ling ZHANG

Jia-qi WANG

Xing LI

Ting LUO

Ling-ying YU

Lu OU

Xiao-qin LI

Related Institution

Key Laboratory of Standardization of Chinese Herbal Medicine，Ministry of Education， College of Pharmacy，Chengdu University of Traditional Chinese Medicine

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

Chengdu Eighth People's Hospital

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰